DGAP-News: Xenikos B.V. / Key word(s): Change of Personnel Xenikos appoints Eric van Hooren as Chief Development Officer to drive forward T-Guard(TM) clinical development program 02.11.2016 / 12:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Xenikos appoints Eric van Hooren as Chief Development Officer to drive forward T-Guard(TM) clinical development program Nijmegen, the Netherlands, November 2nd, 2016 - Xenikos B.V., focused on the development of innovative immunotherapies for the treatment of patients suffering from serious immune diseases or rejection after transplantation, announced today that it has hired Eric van Hooren as Chief Development Officer (CDO). Mr. van Hooren has over 20 years of experience in the pharmaceutical industry, including extensive work in clinical project and clinical trial management. Prior to joining Xenikos, he was Director Clinical Operations at Acerta-Pharma, where he was responsible for the set up and line management of the European clinical operations group, including the execution of Phase 1, 2 and 3 clinical trial programs with the compound acalabrutinib, a potential best-in-class irreversible oral Bruton's tyrosine kinase (BTK) inhibitor, that contributed to a major transaction with AstraZeneca in December 2015. Mr. van Hooren previously worked as a Program Manager at Merck, where he managed Women's Health Programs. He also worked for many years at Organon in positions of increasing responsibility in both clinical development and medical marketing. At Xenikos, Mr. van Hooren will be responsible for preparing and executing the EU/US randomized active-controlled Phase 2 pivotal study of T-Guard in acute graft-versus-host disease (GVHD), as well as exploring new potential indications that might benefit from T-Guard's promise as a therapeutic tool for safely and swiftly resetting the body's immune system in T-cell- mediated diseases. He will take over the responsibilities of Dr. Edna Venneker, who is leaving the company to pursue another opportunity. Xenikos announced just recently that the last patient has completed treatment in the Company's Phase 1/2 trial evaluating T-Guard for the treatment of steroid-resistant acute graft-versus-host disease (GVHD). Ypke van Oosterhout, PhD, Chief Executive Officer, said: "We are delighted to welcome Eric to Xenikos in this very important phase of the T-Guard development. He has a broad background in strategic drug development for both new biological and new chemical entities, as well as in global clinical trial management and medical marketing. His many years of experience will be invaluable as we continue to advance our product candidate, T-Guard in clinical development and eventual registration for market approval in acute graft-versus-host disease, as well as explore other opportunities for this promising development candidate." Dr. van Oosterhout continued: "I would also like to warmly thank Dr. Venneker, who has been instrumental in driving our clinical program. We wish her the very best in her next endeavor." About Xenikos B.V. Xenikos B.V. is developing new, innovative immunotherapies to help restore patients' health and save lives. It is developing new therapies based on the action of conjugated antibodies that enables patients suffering from serious immune diseases or rejection after transplantation to reset their immune systems quickly and efficiently. Its lead product candidate T- Guard(TM) is currently being developed for the second-line treatment of steroid-resistant acute GVHD. Further information is available at www.xenikos.com. For further information, please contact: <pre> Corporate contact: Media contact: Xenikos B.V. MC Services AG Ypke van Oosterhout Dr. Solveigh Mähler Chief Executive Officer Phone: +49 211 529 252 19 Phone: +31 24 3000100 Email: solveigh.maehler@mc-services.eu Mobile: +31 6 11017611 Email: y.vanoosterhout@xenikos.com For US inquiries: Laurie Doyle Phone: +1 339 832 0752 Email: laurie.doyle@mc-services.eu </pre> --------------------------------------------------------------------------- 02.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- 516459 02.11.2016
DGAP-News: Xenikos appoints Eric van Hooren as Chief
Top 10 Most Recent News Articles
Medtronic's Bold Move to Own Carotid Market Full-Scale
When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...
Continue Reading
Berry Street Integrates AI with What Matters: Human Touch
Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...
Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators
Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...
Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza
Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...
Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings
Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...
Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal
Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...
Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids
AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...
Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade
A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...
Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors
A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...
Continue ReadingTop 5 Most Recently Viewed Articles
Empowering Voices: Chicago's Latina Trailblazers Unite
Empowering Voices: Chicago's Latina Trailblazers Unite The Chicago History Museum is set to host a remarkable celebration of the book, Chicago Latina Trailblazers. This event recognizes the contributions of remarkable Latina leaders through compelling narratives of activism and community service. Event Overview On a significant date that marks a celebration of Latina...
Continue Reading
Mark Green to Keynote CyberScape Summit Focused on Cybersecurity
Mark Green to Keynote CyberScape Summit U.S. House Homeland Security Committee Chairman Mark Green is set to showcase his insights as the keynote speaker for GovCIO Media & Research's CyberScape Summit. The event promises to be an essential gathering for those interested in advancing cybersecurity practices and policies within the government. Focus on Cybersecurity and...
Continue Reading
Brian D. Pieninck Takes Leadership Role at GuideWell
Brian D. Pieninck Assumes Role as GuideWell President & CEO GuideWell Mutual Holding Corporation has recently made a significant executive decision by appointing Brian D. Pieninck as the new president and chief executive officer (CEO), effective October 1. Previously, Pieninck served as the president and CEO of CareFirst BlueCross BlueShield and was the Board Chair for...
Continue Reading
Calidi Biotherapeutics Unveils Promising CLD-401 Data at SITC
Calidi Biotherapeutics Showcases CLD-401 at SITC Calidi Biotherapeutics, Inc. (NYSE: CLDI), a clinical-stage biotechnology firm, recently presented impactful new data regarding its lead therapeutic candidate CLD-401 during the Society for Immunotherapy of Cancer (SITC) Annual Meeting. This presentation highlighted the innovative capabilities of Calidi’s RedTail...
Continue Reading
Everlight Solar: Milwaukee's Top Pick for Eco Energy
A High Wattage Win for Everlight Solar Milwaukee seems to have found its favorite solar squad, and it’s none other than Everlight Solar, folks. They’ve locked in the 2026 Milwaukee's Top Choice in the Solar Services Company category. Now, that’s a badge you wear with pride when it's handed out by the very community you serve. It's not every day you see a company...
Continue Reading